A carregar...
Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells
Sorafenib is a multikinase inhibitor used as a first-line treatment for advanced hepatocellular carcinoma (HCC), but it has shown modest to low response rates. The characteristic tumour hypoxia of advanced HCC maybe a major factor underlying hypoxia-mediated treatment failure. Thus, it is urgent to...
Na minha lista:
Publicado no: | Sci Rep |
---|---|
Main Authors: | , , , , , , , , , , , , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
Nature Publishing Group
2016
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4967870/ https://ncbi.nlm.nih.gov/pubmed/27476430 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep30483 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|